A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.

Coleman AL, Lerner F, Bernstein P, Whitcup SM. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003 Dec; 110(12):2362-8.

View in: PubMed

subject areas

Administration, Topical
Adult
Aged
Aged, 80 and over
Amides
Antihypertensive Agents
Cloprostenol
Double-Blind Method
Drug Combinations
Female
Glaucoma
Humans
Intraocular Pressure
Lipids
Male
Middle Aged
Ocular Hypertension
Ophthalmic Solutions
Prospective Studies
Safety
Sulfonamides
Thiophenes
Timolol

authors with profiles

Anne L. Coleman, MD, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support